` NRXP (NRX Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

NRXP
vs
S&P 500

Over the past 12 months, NRXP has significantly outperformed S&P 500, delivering a return of +67% compared to the S&P 500's +14% growth.

Stocks Performance
NRXP vs S&P 500

Loading
NRXP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NRXP vs S&P 500

Performance Gap Between NRXP and GSPC
HIDDEN
Show

Performance By Year
NRXP vs S&P 500

Loading
NRXP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
NRX Pharmaceuticals Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

NRX Pharmaceuticals Inc
Glance View

Market Cap
66.6m USD
Industry
Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB). Its ZYESAMI (aviptadil) is an investigational drug for COVID-19-related respiratory failure. The firm has completed a Phase IIb/III clinical study in patients with acute respiratory failure in COVID-19.

NRXP Intrinsic Value
Not Available
Back to Top